Nicholas Lai

Dr. Nicholas Lai


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Human Gene Therapy
Verified
Journal Article
Closed access
DRDavid A. Roth
David A. Roth
MMM. Dan McKirnan
M. Dan McKirnan
ICIlona Canestrelli
Ilona Canestrelli
MGMei Hua Gao
Mei Hua Gao
NDNancy Dalton
Nancy Dalton
HHH. Kirk Hammond
H. Kirk Hammond
The presence of anti-adenoviral serotype 5 (Ad5) antibodies may limit the efficacy of Ad5-mediated gene transfer. We therefore tested the hypothesis that intracoronary delivery of an adenovirus encoding human fibroblast growth factor type 4 (Ad5.FGF4) would improve regional myocardial function in an animal model of ischemia when high antibody levels preexist or after a prior intracoronary dose of Ad5. High anti-Ad5 antibody levels were generated in pigs by subcutaneous immunization with an adenovirus encoding LacZ (Ad5.lacZ). Neutralizing antibody levels increased 648-fold (range, 82- to 2108-fold) above preimmunization levels, and persisted for the duration of the study. Myocardial function during pacing-induced ischemia was improved in the ischemic region (p<0.001) at both 2 and 4 weeks after Ad5.FGF4 administration despite the presence of preexisting antibodies to Ad5. In a second set of experiments, the efficacy of a second intracoronary administration of Ad5 was determined by exposing the animals first to an intracoronary dose of Ad5.lacZ, followed 7 weeks later by the therapeutic dose of Ad5.FGF4. After delivery of Ad5.lacZ, anti-Ad5 antibody levels increased 8-fold (range, 1- to 18-fold), but this prior exposure to Ad5 did not prevent the therapeutic effects after subsequent intracoronary dosing with Ad5.FGF4 (p<0.001). In the porcine Ameroid constrictor model of myocardial ischemia the presence of anti-Ad5 antibodies or prior intracoronary dosing with adenovirus does not prevent the ability of Ad5.FGF4, delivered by intracoronary injection, from normalizing regional myocardial function.

1 December 2016 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
MGMei Hua Gao
Mei Hua Gao
NLNicholas Lai
Nicholas Lai
DGDimosthenis Giamouridis
Dimosthenis Giamouridis
YKYoung Chul Kim
Young Chul Kim
ZTZhen Tan
Zhen Tan
HHH. Kirk Hammond
H. Kirk Hammond
• Cardiac-targeted expression of C1C2 reduces cAMP production yet mice maintain normal cardiac function through increased Ca2+ handling. • Sustained isoproterenol infusion reduces heart function in normal mice, but improves heart function in mice with increased cardiac C1C2 expression. • Reduced cardiac cAMP generation and resistance to catecholamine cardiomyopathy are attractive features of this potential heart failure therapeutic. • Removing the large transmembrane domains of AC6 and fusing the two intracellular domains provides a small molecule, C1C2, that replicates many of the beneficial effects of AC6, but is sufficiently small to be expressed in an AAV vector for gene transfer.

1 August 2006 in JACC
Verified
Journal Article
Closed access
ASAshwani Sastry
Ashwani Sastry
EAElizabeth Arnold
Elizabeth Arnold
HGHunaid Gurji
Hunaid Gurji
AIAtsushi Iwasa
Atsushi Iwasa
HBHanh Bui
Hanh Bui
SNSanjiv M. Narayan
Sanjiv M. Narayan

1 October 1998 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
TAToshihisa Anzai
Toshihisa Anzai
NLNicholas Lai
Nicholas Lai
MGMeihua Gao
Meihua Gao
HHH. Kirk Hammond
H. Kirk Hammond
We have previously shown that left ventricular (LV) pacing-induced heart failure is associated with preserved wall thickening in the interventricular septum (IVS) compared with the posterolateral wall (PLW). The current study focuses on the relationship between regional myocardial function and altered β-adrenergic receptor (β-AR) signaling. We studied 15 pigs: 6 controls and 9 paced from the left ventricle (225 beats/min, 26 ± 3 days). Heart failure was documented by decreased LV fractional shortening (P < 0.0001) and increased left atrial pressure (P < 0.0001). In heart failure, despite marked differences in basal regional function (percent wall thickening: IVS, 33 ± 10% vs. PLW, 13 ± 7%; P = 0.0003), there were no differences between the two regions in β-AR responsiveness, measured by regional wall thickening in response to dobutamine infusion and any measurement of adrenergic signaling. Adenylyl cyclase activity, β-AR number, and β-AR/Gscoupling were markedly reduced in failing LV without regional differences. In animals with heart failure, LV G protein receptor kinase (GRK) isoform 2 content was unchanged and GRK5, the other major GRK isoform, was increased more than threefold (IVS, 0.51 ± 0.20 vs. 0.12 ± 0.12 arbitrary densitometric units,P = 0.01; PLW, 0.47 ± 0.15 vs. 0.13 ± 0.09 arbitrary densitometric units,P = 0.03), but again, there were no regional differences. These data indicate that systemic rather than regional factors govern LV adrenergic signaling and that regional adrenergic signaling abnormalities poorly predict wall thickening in the same regions.

15 September 1994
Verified
Book Chapter
Closed access
JGJ.B. Graham
J.B. Graham
HDH. Dewar
H. Dewar
NLNicholas Lai
Nicholas Lai
KKK.E. Korsmeyer
K.E. Korsmeyer
PFPeter Fields
Peter Fields
RBRichard Walter Brill
Richard Walter Brill
The Mechanics and Physiology of Animal Swimming - September 1994

30 May 2025 in Journal of Feline Medicine and Surgery
Verified
Journal Article
Open access
NLNicholas Lai
Nicholas Lai
SNSandra M Nguyen
Sandra M Nguyen
JTJohanna E Todd
Johanna E Todd
VLVeronika Langova
Veronika Langova
SBSpela Bavcar
Spela Bavcar
JWJoanna D White
Joanna D White
Objectives: This study aimed to compare the response rate, progression-free interval (PFI), survival time (ST) and adverse events in cats treated with cyclophosphamide, mitoxantrone, vincristine and prednisolone (CMOP) vs cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for intermediate- to large-cell feline lymphoma. Methods: Medical records of cats treated for intermediate- to large-cell lymphoma between 2015 and 2023 from three referral institutions within the larger Sydney metropolitan area were retrospectively reviewed. Cats were included if they had a confirmed diagnosis of intermediate- to large-cell lymphoma and had received either a CMOP or CHOP protocol as a first-line treatment. Statistical analysis was conducted to determine if PFI or ST differed significantly between treatment groups. A multivariate analysis was also conducted to determine whether differences in prognostic factors between the groups may have biased outcomes. Results: A total of 123 cats were enrolled, with 41 cats in the CMOP group and 82 cats in the CHOP group. No significant differences were identified between the response rates (66% in both groups), median PFI (CMOP 69 days, CHOP 59 days) and median ST (CMOP 103 days, CHOP 80 days) of cats treated with CMOP instead of CHOP. Conclusions and relevance: CMOP is a well-tolerated and suitable substitute for CHOP for feline intermediate- to large-cell lymphoma. It is logistically easier to administer as it can be given as an intravenous bolus and carries less risk of catastrophic extravasation injuries.